Switch to:
Also traded in: Austria, Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.18
HOLX's Cash-to-Debt is ranked lower than
88% of the 197 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.69 vs. HOLX: 0.18 )
Ranked among companies with meaningful Cash-to-Debt only.
HOLX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.04  Med: 2.4 Max: No Debt
Current: 0.18
Equity-to-Asset 0.35
HOLX's Equity-to-Asset is ranked lower than
82% of the 188 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.60 vs. HOLX: 0.35 )
Ranked among companies with meaningful Equity-to-Asset only.
HOLX' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.02  Med: 0.7 Max: 0.88
Current: 0.35
0.02
0.88
Debt-to-Equity 1.13
HOLX's Debt-to-Equity is ranked lower than
83% of the 145 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.35 vs. HOLX: 1.13 )
Ranked among companies with meaningful Debt-to-Equity only.
HOLX' s Debt-to-Equity Range Over the Past 10 Years
Min: 0  Med: 0.22 Max: 10
Current: 1.13
0
10
Debt-to-EBITDA 1.74
HOLX's Debt-to-EBITDA is ranked higher than
54% of the 109 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.93 vs. HOLX: 1.74 )
Ranked among companies with meaningful Debt-to-EBITDA only.
HOLX' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -103.43  Med: 2.77 Max: 11.87
Current: 1.74
-103.43
11.87
Interest Coverage 9.09
HOLX's Interest Coverage is ranked lower than
73% of the 137 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 44.21 vs. HOLX: 9.09 )
Ranked among companies with meaningful Interest Coverage only.
HOLX' s Interest Coverage Range Over the Past 10 Years
Min: 0.55  Med: 2.21 Max: 71.1
Current: 9.09
0.55
71.1
Piotroski F-Score: 5
Altman Z-Score: 1.63
Beneish M-Score: -1.87
WACC vs ROIC
5.24%
17.17%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 47.20
HOLX's Operating Margin % is ranked higher than
97% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.72 vs. HOLX: 47.20 )
Ranked among companies with meaningful Operating Margin % only.
HOLX' s Operating Margin % Range Over the Past 10 Years
Min: -123.18  Med: 8.37 Max: 47.2
Current: 47.2
-123.18
47.2
Net Margin % 25.64
HOLX's Net Margin % is ranked higher than
94% of the 193 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.03 vs. HOLX: 25.64 )
Ranked among companies with meaningful Net Margin % only.
HOLX' s Net Margin % Range Over the Past 10 Years
Min: -135.4  Med: -1.5 Max: 25.64
Current: 25.64
-135.4
25.64
ROE % 31.67
HOLX's ROE % is ranked higher than
94% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.68 vs. HOLX: 31.67 )
Ranked among companies with meaningful ROE % only.
HOLX' s ROE % Range Over the Past 10 Years
Min: -60.17  Med: -0.73 Max: 31.67
Current: 31.67
-60.17
31.67
ROA % 9.86
HOLX's ROA % is ranked higher than
79% of the 197 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.36 vs. HOLX: 9.86 )
Ranked among companies with meaningful ROA % only.
HOLX' s ROA % Range Over the Past 10 Years
Min: -32.08  Med: -0.35 Max: 9.86
Current: 9.86
-32.08
9.86
ROC (Joel Greenblatt) % 180.08
HOLX's ROC (Joel Greenblatt) % is ranked higher than
99% of the 196 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.63 vs. HOLX: 180.08 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
HOLX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -369.68  Med: 25.23 Max: 180.08
Current: 180.08
-369.68
180.08
3-Year Revenue Growth Rate 2.20
HOLX's 3-Year Revenue Growth Rate is ranked lower than
58% of the 162 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.90 vs. HOLX: 2.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
HOLX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -14.1  Med: 10.3 Max: 41.9
Current: 2.2
-14.1
41.9
GuruFocus has detected 1 Warning Sign with Hologic Inc HOLX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» HOLX's 30-Y Financials

Financials (Next Earnings Date: 2017-11-08)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2016

HOLX Guru Trades in Q4 2016

Jim Simons 1,463,618 sh (+148.06%)
Pioneer Investments 173,374 sh (+102.03%)
Joel Greenblatt Sold Out
George Soros Sold Out
Robert Olstein 184,000 sh (-1.60%)
Kahn Brothers 1,197,404 sh (-3.01%)
Steven Cohen 1,142,100 sh (-13.19%)
Vanguard Health Care Fund 3,538,200 sh (-48.69%)
Paul Tudor Jones 500,000 sh (-58.33%)
» More
Q1 2017

HOLX Guru Trades in Q1 2017

Eaton Vance Worldwide Health Sciences Fund 491,712 sh (New)
Vanguard Health Care Fund 3,538,200 sh (unchged)
Paul Tudor Jones Sold Out
Steven Cohen Sold Out
Jim Simons 1,456,318 sh (-0.50%)
Pioneer Investments 172,100 sh (-0.73%)
Robert Olstein 167,000 sh (-9.24%)
Kahn Brothers 918,399 sh (-23.30%)
» More
Q2 2017

HOLX Guru Trades in Q2 2017

Caxton Associates 13,100 sh (New)
Chuck Royce 20,000 sh (New)
Joel Greenblatt 41,201 sh (New)
Lee Ainslie 88,510 sh (New)
Vanguard Health Care Fund 3,538,200 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 491,712 sh (unchged)
Kahn Brothers 799,465 sh (-12.95%)
Jim Simons 1,227,118 sh (-15.74%)
Pioneer Investments 94,897 sh (-44.86%)
Robert Olstein 91,500 sh (-45.21%)
» More
Q3 2017

HOLX Guru Trades in Q3 2017

Jerome Dodson 476,556 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with HOLX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Kahn Brothers 2017-06-30 Reduce -12.95%0.87%$42.23 - $46.49 $ 36.81-17%799,465
Robert Olstein 2017-06-30 Reduce -45.21%0.41%$42.23 - $46.49 $ 36.81-17%91,500
Joel Greenblatt 2017-06-30 New Buy0.03%$42.23 - $46.49 $ 36.81-17%41,201
Kahn Brothers 2017-03-31 Reduce -23.30%1.89%$39.03 - $42.78 $ 36.81-10%918,399
Robert Olstein 2017-03-31 Reduce -9.24%0.09%$39.03 - $42.78 $ 36.81-10%167,000
Vanguard Health Care Fund 2016-12-31 Reduce -48.69%0.28%$35.37 - $40.79 $ 36.81-5%3,538,200
Kahn Brothers 2016-12-31 Reduce -3.01%0.26%$35.37 - $40.79 $ 36.81-5%1,197,404
Robert Olstein 2016-12-31 Reduce -1.60%0.02%$35.37 - $40.79 $ 36.81-5%184,000
Joel Greenblatt 2016-12-31 Sold Out 0.05%$35.37 - $40.79 $ 36.81-5%0
George Soros 2016-12-31 Sold Out 0.01%$35.37 - $40.79 $ 36.81-5%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies    NAICS: 334517    SIC: 3844
Compare:XSWX:STMN, NYSE:RMD, NYSE:COO, TSE:7733, NYSE:STE, NAS:XRAY, NYSE:WST, TSE:4543, NYSE:WAT, SZSE:002294, NYSE:HRC, NYSE:MTD, OSTO:GETI B, NAS:ICUI, NYSE:CMD, OCSE:COLO B, MIL:AMP, NAS:PODD, TSE:7747, OSTO:LIFCO B » details
Traded in other countries:HOLX.Austria, HO1.Germany,
Headquarter Location:USA
Hologic Inc develops, manufactures and supplies diagnostics products, medical imaging systems and surgical products for women's health. Its products are used in diagnosis of human diseases and screen donated human blood and plasma.

Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (47% of sales), breast health (37%), surgical (12%), and skeletal health (4%). While the company traditionally focused on breast health, the recent acquisition of Gen-Probe puts a much greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (74%), followed by Europe (12%) and Asia (8%). Hologic is headquartered in Bedford, Massachusetts.

Top Ranked Articles about Hologic Inc

Jerome Dodson Starts 5 New Positions in 3rd Quarter Guru reports quarterly portfolio
Parnassus Fund manager Jerome Dodson (Trades, Portfolio) seeks long-term capital appreciation through securities with the following characteristics: wide competitive advantages, good management quality and “relevancy over the long term.” Read more...
Panther Fusion® Flu A/B/RSV Assay Now FDA Cleared on Hologic's New Panther Fusion® System
Hologic Announces Pricing of Offering of $350 Million Aggregate Principal Amount of 4.375% Senior Notes Due 2025
Hologic Announces Offering of $350 Million of Senior Notes Due 2025
Hologic Enters into Amended and Restated Five-Year Secured Credit Agreement
Hologic to Announce Financial Results for the Fourth Quarter of Fiscal 2017 on Wednesday, November 8, 2017
Hologic, Inc. (Nasdaq: HOLX) to Ring The Nasdaq Stock Market Opening Bell
Hologic CEO Steve MacMillan to Ring Nasdaq Opening Bell on October 2 to Kick Off Breast Cancer Awareness Month
Hologic Receives FDA 510(k) Clearance to Market SculpSure® for Non-Invasive Body Contouring (Lipolysis) of the Submental Area (Under the Chin)
Hologic Introduces a More Comfortable Mammogram with the Launch of the SmartCurve™ Breast Stabilization System

Ratios

vs
industry
vs
history
PE Ratio 13.73
HOLX's PE Ratio is ranked higher than
87% of the 120 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 31.08 vs. HOLX: 13.73 )
Ranked among companies with meaningful PE Ratio only.
HOLX' s PE Ratio Range Over the Past 10 Years
Min: 13.4  Med: 49.66 Max: 472.67
Current: 13.73
13.4
472.67
Forward PE Ratio 16.56
HOLX's Forward PE Ratio is ranked higher than
92% of the 40 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 25.51 vs. HOLX: 16.56 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 13.73
HOLX's PE Ratio without NRI is ranked higher than
87% of the 120 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 31.48 vs. HOLX: 13.73 )
Ranked among companies with meaningful PE Ratio without NRI only.
HOLX' s PE Ratio without NRI Range Over the Past 10 Years
Min: 13.4  Med: 49.66 Max: 472.67
Current: 13.73
13.4
472.67
Price-to-Owner-Earnings 14.37
HOLX's Price-to-Owner-Earnings is ranked higher than
82% of the 84 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 30.51 vs. HOLX: 14.37 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
HOLX' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 8.31  Med: 23.68 Max: 145.14
Current: 14.37
8.31
145.14
PB Ratio 3.59
HOLX's PB Ratio is ranked lower than
54% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.25 vs. HOLX: 3.59 )
Ranked among companies with meaningful PB Ratio only.
HOLX' s PB Ratio Range Over the Past 10 Years
Min: 0.59  Med: 2 Max: 5.65
Current: 3.59
0.59
5.65
PS Ratio 3.51
HOLX's PS Ratio is ranked lower than
51% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.36 vs. HOLX: 3.51 )
Ranked among companies with meaningful PS Ratio only.
HOLX' s PS Ratio Range Over the Past 10 Years
Min: 1.47  Med: 2.93 Max: 5.55
Current: 3.51
1.47
5.55
Price-to-Operating-Cash-Flow 160.74
HOLX's Price-to-Operating-Cash-Flow is ranked lower than
94% of the 93 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 19.95 vs. HOLX: 160.74 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
HOLX' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 5.51  Med: 13.08 Max: 201.44
Current: 160.74
5.51
201.44
EV-to-EBIT 9.14
HOLX's EV-to-EBIT is ranked higher than
88% of the 121 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 25.17 vs. HOLX: 9.14 )
Ranked among companies with meaningful EV-to-EBIT only.
HOLX' s EV-to-EBIT Range Over the Past 10 Years
Min: -137.4  Med: 24.6 Max: 153.7
Current: 9.14
-137.4
153.7
EV-to-EBITDA 6.98
HOLX's EV-to-EBITDA is ranked higher than
89% of the 134 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 18.83 vs. HOLX: 6.98 )
Ranked among companies with meaningful EV-to-EBITDA only.
HOLX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -344.2  Med: 12.5 Max: 100.6
Current: 6.98
-344.2
100.6
EV-to-Revenue 4.35
HOLX's EV-to-Revenue is ranked lower than
55% of the 191 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.54 vs. HOLX: 4.35 )
Ranked among companies with meaningful EV-to-Revenue only.
HOLX' s EV-to-Revenue Range Over the Past 10 Years
Min: 2.6  Med: 4.3 Max: 10.1
Current: 4.35
2.6
10.1
Current Ratio 0.85
HOLX's Current Ratio is ranked lower than
94% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.57 vs. HOLX: 0.85 )
Ranked among companies with meaningful Current Ratio only.
HOLX' s Current Ratio Range Over the Past 10 Years
Min: 0.85  Med: 2.87 Max: 7.31
Current: 0.85
0.85
7.31
Quick Ratio 0.65
HOLX's Quick Ratio is ranked lower than
90% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.88 vs. HOLX: 0.65 )
Ranked among companies with meaningful Quick Ratio only.
HOLX' s Quick Ratio Range Over the Past 10 Years
Min: 0.65  Med: 2.28 Max: 6.57
Current: 0.65
0.65
6.57
Days Inventory 82.61
HOLX's Days Inventory is ranked higher than
76% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 131.23 vs. HOLX: 82.61 )
Ranked among companies with meaningful Days Inventory only.
HOLX' s Days Inventory Range Over the Past 10 Years
Min: 65.34  Med: 88.04 Max: 108.2
Current: 82.61
65.34
108.2
Days Sales Outstanding 63.67
HOLX's Days Sales Outstanding is ranked lower than
58% of the 163 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 61.37 vs. HOLX: 63.67 )
Ranked among companies with meaningful Days Sales Outstanding only.
HOLX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 56.15  Med: 60.73 Max: 75.51
Current: 63.67
56.15
75.51
Days Payable 39.51
HOLX's Days Payable is ranked lower than
62% of the 152 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 51.31 vs. HOLX: 39.51 )
Ranked among companies with meaningful Days Payable only.
HOLX' s Days Payable Range Over the Past 10 Years
Min: 21.81  Med: 27.28 Max: 45.11
Current: 39.51
21.81
45.11

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -0.70
HOLX's 3-Year Average Share Buyback Ratio is ranked higher than
71% of the 137 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -4.10 vs. HOLX: -0.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
HOLX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -53.1  Med: -6.1 Max: -0.7
Current: -0.7
-53.1
-0.7

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.70
HOLX's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
64% of the 84 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.18 vs. HOLX: 1.70 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
HOLX' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.45  Med: 1.7 Max: 13.86
Current: 1.7
0.45
13.86
Price-to-Median-PS-Value 1.20
HOLX's Price-to-Median-PS-Value is ranked lower than
54% of the 166 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.12 vs. HOLX: 1.20 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
HOLX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.15  Med: 0.81 Max: 2.58
Current: 1.2
0.15
2.58
Earnings Yield (Greenblatt) % 10.94
HOLX's Earnings Yield (Greenblatt) % is ranked higher than
93% of the 197 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.49 vs. HOLX: 10.94 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
HOLX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -49.1  Med: 2.6 Max: 11.16
Current: 10.94
-49.1
11.16
Forward Rate of Return (Yacktman) % 26.03
HOLX's Forward Rate of Return (Yacktman) % is ranked higher than
87% of the 97 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.48 vs. HOLX: 26.03 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
HOLX' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 2.9  Med: 6.9 Max: 72.7
Current: 26.03
2.9
72.7

More Statistics

Revenue (TTM) (Mil) $2,982.80
EPS (TTM) $ 2.68
Beta0.59
Short Percentage of Float3.49%
52-Week Range $35.15 - 46.80
Shares Outstanding (Mil)280.47

Analyst Estimate

Sep17 Sep18 Sep19 Sep20
Revenue (Mil $) 3,045 3,312 3,530 3,722
EPS ($) 1.97 2.16 2.37 2.60
EPS without NRI ($) 1.97 2.16 2.37 2.60
EPS Growth Rate
(Future 3Y To 5Y Estimate)
8.87%
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 55
Positive ROAY
Positive CFROAY
Higher ROA yoyY
CFROA > ROAN
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}